Gastroesophageal reflux disease, obesity and laparoscopic sleeve gastrectomy: The burning questions

Halim Bou Daher, Ala I Sharara

Abstract Obesity is a global health epidemic with considerable economic burden. Surgical solutions have become increasingly popular following technical advances leading to sustained efficacy and reduced risk. Sleeve gastrectomy accounts for almost half of all bariatric surgeries worldwide but concerns regarding its relationship with gastroesophageal reflux disease (GERD) has been a topic of debate. GERD,including erosive esophagitis, is highly prevalent in the obese population. The role of pre-operative endoscopy in bariatric surgery has been controversial. Two schools of thought exist on the matter, one that believes routine upper endoscopy before bariatric surgery is not warranted in the absence of symptoms and another that believes that symptoms are poor predictors of underlying esophageal pathology. This debate is particularly important considering the evidence for the association of laparoscopic sleeve gastrectomy (LSG) with de novo and/or worsening GERD compared to the less popular Roux-en-Y gastric bypass procedure. In this paper, we try to address 3 burning questions regarding the inter-relationship of obesity, GERD, and LSG: (1) What is the prevalence of GERD and erosive esophagitis in obese patients considered for bariatric surgery? (2) Is it necessary to perform an upper endoscopy in obese patients considered for bariatric surgery? And (3) What are the long-term effects of sleeve gastrectomy on GERD and should LSG be done in patients with pre-existing GERD?

Key words: Reflux; Erosive; Acid; Bariatric; Obesity; Gastric bypass; Endoscopy

INTRODUCTION

Obesity is a modern-day global epidemic with significant health and economic burden. According to the World Health Organization, 650 million adults (13% of all adults) and over 340 million children and adolescents are overweight or obese[1]. In light of the oft-disappointing long-term results of medical and behavioral interventions, an increasingly larger number of obese patients are turning to minimally invasive bariatric surgery. According to the American Society for Metabolic and Bariatric Surgery, approximately 216000 individuals underwent bariatric surgery in 2016 in the United States, a net increase of 36.7% over a five-year period starting in 2011[2]. Laparoscopic sleeve gastrectomy (LSG) is currently the most popular procedure accounting for more than 50% to 60% of bariatric surgeries worldwide[2,3]. Two recent large randomized trials have confirmed that there is no significant difference in excess weight loss between LSG and laparoscopic Roux-en-Y gastric bypass (RYGB) at 5 years of follow-up[4,5]. However, enthusiasm for this relatively simple procedure has been curtailed by concerns of post-operative gastroesophageal reflux disease (GERD), as a result of either persistent or de novo reflux[2]. This remains an issue of significant controversy and active debate in clinical practice. At the Fifth International Consensus Conference on LSG, 52.5% of general surgeons and 23.3% of bariatric experts considered GERD a contraindication to LSG[6].This article will address 3 burning questions concerning the inter-relationship between obesity, GERD, and LSG.

WHAT IS THE PREVALENCE OF GERD AND EROSIVE ESOPHAGITIS IN OBESE PATIENTS CONSIDERED FOR BARIATRIC SURGERY?

Obesity is an important risk factor for GERD and is associated with esophageal complications such as erosive esophagitis (EE), Barrett's esophagus, and esophageal adenocarcinoma[7,8]. GERD has been reported in as many as 62.4% to 73% of bariatric surgery candidates[9,10]. The pathophysiological mechanisms predisposing to GERD in obesity include increased intra-abdominal pressure[11], impaired gastric emptying[12],decreased lower esophageal sphincter (LES) pressure, and higher frequency of transient LES relaxation[13,14]. In addition, a higher prevalence of hiatal hernia has been described in obese individuals[15]. Central obesity, rather than body mass index (BMI),is more closely associated with GERD[7,16]. High-resolution manometry suggests that both intragastric pressure and gastroesophageal pressure gradient correlate primarily with waist circumference[10].

Overweight and obesity (especially abdominal visceral obesity) are also risk factors for EE. EE is associated with higher distal acid exposure time (percentage time with pH ＜ 4) and higher percentage of reflux episodes reaching the proximal esophagus[17].El-Serag et al[7]showed that patients with a BMI ＞ 30 are 2.5 times more likely to have reflux symptoms and EE than those with a normal BMI. A meta-analysis of 6 studies showed that the adjusted risk ratio for EE was 1.76 in patients with BMI ＞ 25 compared to those with BMI ＜ 25[18]. Prospective endoscopic studies in bariatric surgery candidates have documented a high prevalence of EE in obese individuals ranging from 4.2% to 33.9% (Table 1)[9-11,19-25]. Risk factors for EE varied between studies and included increased waist circumference, insulin resistance, and presence of reflux symptoms[11]. It is important to note that the absence of symptoms does not exclude erosive disease. In one study, 12.3% of obese patients with low probability of reflux symptoms (low GERDQ score ＜ 8) had EE[9]. The literature is conclusive on the matter: Obesity is associated with higher prevalence of GERD and erosive esophagitis.

Table 1 Prospective studies on the prevalence of erosive esophagitis in obese patients

IS IT NECESSARY TO DO AN UPPER ENDOSCOPY IN OBESE PATIENTS CONSIDERED FOR BARIATRIC SURGERY?

Clinical practice guidelines published in 2013 by the American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic and Bariatric Surgery recommend preoperative endoscopy only when clinically indicated[26]. This is in line with the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2008 guidelines and the 2014 interdisciplinary European guidelines endorsed by the International Federation for the Surgery of Obesity and Metabolic Disorders-European Chapter and European Association for the Study of Obesity[27]. On the other hand, the 2015 ASGE guidelines recommend that the decision be individualized[28]while the European Association of Endoscopic Surgeons advises that all patients be evaluated by either endoscopy or upper gastrointestinal series prior to their bariatric surgery[29]. In short, the jury is still out on the matter and a consensus between international and national societies seems unlikely. In a recent series of 1555 patients, asymptomatic patients with significant findings on endoscopy did not require a change in management or surgery[30]. The authors went on to conclude that routine upper endoscopy requires further justifications for asymptomatic patients. On the other hand, several recent studies emphasized the importance of doing an upper endoscopy preoperatively[23-25]. Carabotti et al[24]showed that the incidence of endoscopic lesions was the same between patients who reported symptoms and those who did not; the study also concluded that with the current adopted approach to preoperative endoscopy, 87% of EE cases would have been missed. In our experience, we had similar outcomes when we administered the GERD-Q and the Nocturnal GERD Symptom Severity and Impact Questionnaire (NGSSIQ) to more than 240 consecutive unselected patients scheduled for bariatric surgery. These validated scores were poorly predictive of endoscopically-proven EE in these patients, even when combined with clinical assessment as part of a composite score[9]. As mentioned earlier, the absence of symptoms does not rule out the presence of GERD[9,23]. A recent survey conducted in the United Kingdom showed that 90% of bariatric units perform preoperative upper endoscopy either routinely or selectively[31]. However, there is also no clear consensus on the indications amongst those who do it selectively. This is particularly important in patients considered for LSG given the evidence linking it to worsening GERD and PPI dependence[32-34]. The reason so much debate surrounds the issue is because significant GERD plays a major role in the choice of the bariatric procedure and the presence of per-operative reflux symptoms appears to be associated with post-operative GERD[35]. In the absence of proper randomized trials and dedicated large long-term follow-up studies, the impact of baseline GERD as well as its post-operative risk should be thoroughly discussed with the patient to help guide the choice of the bariatric procedure. We recommend routine upper endoscopy for all patients scheduled to undergo bariatric surgery to assist with this shared decision process.

WHAT ARE THE LONG-TERM EFFECTS OF SLEEVE GASTRECTOMY ON GERD? AND SHOULD LSG BE DONE IN PATIENTS WITH PRE-EXISTING GERD?

Several short-term (less than 2 years) follow-up studies have looked at the effect of sleeve gastrectomy on GERD. Some have shown improvement of GERD symptoms after LSG[36-40]while others reported worsening and de novo GERD[41-45]. Few studies have objectively evaluated the presence of pathologic reflux by 24-h multichannel intraluminal impedance pH monitoring at ≥ 12 mo after LSG reporting conflicting results[46-50]. A systematic review and meta-analysis was inconclusive reporting “high heterogeneity among available studies and paradoxical outcomes of objective esophageal function tests”[32]. Recently, two large randomized controlled trials were published comparing the 5-year follow-up outcome of LSG and RYGB[4,5]. The SMBOSS trial reported 5-year postoperative GERD remission in 25% in the LSG group compared to 60.4% in RYGB (P = 0.002) with de novo GERD in 31.6% of LSG patients compared to 10.7% in RYGB patients (P = 0.01). The study also reported that 9% of LSG patients had to undergo conversion to RYGB because of GERD (highest reason for conversion in the study population). The SLEEVEPASS trial reported RYGB conversion in 6% due to reflux (the study excluded patients with “severe gastroesophageal reflux with a large hiatal hernia”). These figures are consistent with previous literature that showed a 5%-10% conversion rate from LSG to RYGB due to GERD[35,51]. A systematic review published in 2016 demonstrated that 8 out of 10 studies showed new onset GERD at long-term follow up after LSG with a range of 10% to 23%[52]. A prospective study by Genco et al. of 110 LSG patients followed over a mean of 58 months showed that the incidence of GERD symptoms, EE and PPI intake increased significantly post-operatively. Upward migration of the GEJ Z-line was found in 73.6% of cases on follow-up endoscopy. What was most alarming in this study was the fact that non-dysplastic Barrett's esophagus was newly diagnosed in 17.2% of patients. This finding has been duplicated in another recent small multicenter study from Italy[53].

The lines of evidence supporting that LSG is a refluxogenic procedure are multiple and include the observation of increased intragastric pressure and impedance reflux episodes on high-resolution impedance manometry after LSG[54], significant increase in non-acidic reflux with stasis and acidification in esophagus, and the higher rate of de novo reflux in cohort studies and in randomized controlled studies compared to RYGB. In a rat model, LSG was independently associated with histopathologic changes of severe esophagitis compared to high-fat diet fed and to sham-operated rats[55]. The putative pathophysiological mechanisms underlying GERD after LSG are summarized in Table 2[49,56-62]. They include a hypotensive LES, loss of angle of His flap valve, increased gastroesophageal pressure gradient with intra-thoracic migration of the remnant stomach, reduction in the compliance of the gastric remnant provoking an increase in transient LES relaxations, relative gastric stasis in the proximal remnant and increased emptying from the antrum, stasis and acidification in the esophagus, as well as higher intragastric pressure and increased impedance reflux episodes. Figure 1 showcases some of the endoscopic and radiologic findings of GERD post LSG.

Given the evidence for long-term GERD burden post LSG, the 2015 joint statement by the ASMBS, SAGES and ASGE considered EE as a relative contraindication to the surgery[28]. A recent prospective study showed that the presence of pre-operative GERD symptoms and EE at baseline were independently associated with a higher need of postoperative PPI use at 6 mo after LSG[34]. The totality of the evidence suggests that LSG is associated with an increased incidence of GERD. While some obese patients with mild non-erosive reflux disease may benefit from LSG with resolution of GERD symptoms after weight loss, those with severe reflux and erosive disease appear to have a high probability of persistent GERD. The opportunity to save such patients from persistent gastroesophageal reflux, PPI dependence, and possible revisional surgery should be seized and the available evidence openly discussed with the patient.

CONCLUSION

The popularity of sleeve gastrectomy derives mainly from its relative ease, safety and efficacy. The “Achilles heel” of this procedure appears to be gastroesophageal reflux and its complications. This is an issue of concern particularly for patients with preexisting GERD or EE. As physicians, we have a duty not to cause harm. We believe that a thorough evaluation of reflux symptoms as well as esophageal anatomy and pathology should be systematically undertaken in all patients considered for bariatric surgery. This should be followed by an informed and open discussion with the patient about risks and benefits of different bariatric surgical options leading to optimal shared decision making.

Table 2 Putative pathophysiological mechanisms of gastroesophageal reflux disease post laparoscopic sleeve gastrectomy

Figure 1 Erosive esophagitis and gastroesophageal reflux. A: Erosive esophagitis in a patient with de novo reflux symptoms post laparoscopic sleeve gastrectomy; B: Barium upper gastrointestinal series demonstrating gastroesophageal reflux in a patient post laparoscopic sleeve gastrectomy.